HIPERTENSION

ENSAYOS CLINICOS


ENSAYOS CLINICOS

Effects of eplerenone versus losartan in patients with low-renin hypertension
REVISTA: Am Heart J.

The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
REVISTA: J Am Coll Cardiol.

Tratamiento de pacientes Non-Dipper con administracción nocturna de Valsartan
REVISTA: J Hypertens.

Is low-risk hypertension fact or fiction? cardiovascular risk profile in the TROPHY study
REVISTA: Am J Hypertens.

ASCOT-HTA: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial
REVISTA: Lancet

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).
REVISTA: Stroke

Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study
REVISTA: Act Diabetol

Publicado el Estudio BENEDICT: Prevención de Microalbuminuria en Hipertensos con Diabetes Tipo 2 con Trandolapril y Verapamilo
REVISTA: NEJM

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).
REVISTA: Lancet

Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial
REVISTA: Journal of Hypertension

Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial.
REVISTA: Lancet

Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE. Resultados del Estudio SCCOPE en Calidad de vida
REVISTA: Journal of Human Hypertension

Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial
REVISTA: Am J Hypertens

Effects of different blood pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Blood Pressure Lowering Trialists (BPLT).
REVISTA: Lancet

Influence of weight reduction on blood pressure. A meta-analysis of randomized controlled trials.
REVISTA: Hypertension

A Calcium Antagonist vs a Non–Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease The International Verapamil-Trandolapril Study (INVEST): A Randomized Controlled Trial
REVISTA: JAMA

PROGRESS: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack.
REVISTA: Lancet

INSIGHT: Subestudio de pacientes hipertensos diabéticos: Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT).
REVISTA: Hypertension

LIFE: Subestudio de pacientes con Hipertensión Sistólica Aislada: Effects of Losartan on Cardiovascular Morbidity and Mortality in Patients With Isolated Systolic Hypertension and Left Ventricular Hypertrophy
REVISTA: JAMA

ALLHAT: ALLHAT-Heart Attack Prevention Trial
REVISTA:

MICRO-HOPE: Effects of Ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: result of HOPE study and MICRO-HOPE substudy.
REVISTA: Lancet

HOPE: Effects of an angiotensin-converting enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients.
REVISTA: N Engl J Med

RENAAL: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
REVISTA: N Engl J Med

IRMA II : The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
REVISTA: N Engl J Med

IDNT: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
REVISTA: N Engl J Med

LIFE: Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) sub-study.
REVISTA: JAMA

LIFE: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
REVISTA: Lancet

LIFE: http://www.liifetrial.com/country/es/entry/home.html
REVISTA: LIIFETRIAL.COM

ALLHAT: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
REVISTA: JAMA